Detail akcie Palvella Thera Rg online

Business Summary: Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Palvella Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $14.1M to $29M. Higher net loss reflects Research and development - other increase from $5.2M to $14.2M (expense), General and administrative - other increase from $4M to $8.7M (expense), Stock-based Compensation in SGA increase from $125K to $2.8M (expense).